Detalhe da pesquisa
1.
Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency.
N Engl J Med
; 384(21): 2002-2013, 2021 05 27.
Artigo
Inglês
| MEDLINE | ID: mdl-33974366
2.
Best practice for analysis of shared clinical trial data.
BMC Med Res Methodol
; 16 Suppl 1: 76, 2016 Jul 08.
Artigo
Inglês
| MEDLINE | ID: mdl-27410240
3.
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
N Engl J Med
; 354(9): 899-910, 2006 Mar 02.
Artigo
Inglês
| MEDLINE | ID: mdl-16510744
4.
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
N Engl J Med
; 354(9): 911-23, 2006 Mar 02.
Artigo
Inglês
| MEDLINE | ID: mdl-16510745
5.
Health-related quality of life in multiple sclerosis: effects of natalizumab.
Ann Neurol
; 62(4): 335-46, 2007 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-17696126
6.
Conditional approval: discussion points from the PSI conditional approval expert group.
Pharm Stat
; 7(4): 263-9; discussion 270-1, 2008.
Artigo
Inglês
| MEDLINE | ID: mdl-17847030
7.
Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS.
Neurology
; 80(16): 1509-17, 2013 Apr 16.
Artigo
Inglês
| MEDLINE | ID: mdl-23535489
8.
Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS.
J Neurol
; 259(5): 898-905, 2012 May.
Artigo
Inglês
| MEDLINE | ID: mdl-22008873
9.
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
J Neurol Sci
; 292(1-2): 28-35, 2010 May 15.
Artigo
Inglês
| MEDLINE | ID: mdl-20236661
10.
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.
J Neurol
; 256(3): 405-15, 2009 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-19308305